Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ayad Atra & C. Ross Pinkerton. (1996) Special Section: Autologous Stem Cell Transplantations in Solid Tumours: Autologous Stem Cell Transplantation in Solid Tumours of Childhood. Annals of Medicine 28:2, pages 159-164.
Read now
Read now
Jukka Rajantie, Sakari Wikström, Mikko Perkkiö, Liisa Hovi, Anne Mäkipernaa, Eeva-Liisa Maunuksela & Martti A. Siimes. (1988) Improved Prognosis for Children with Stage IV Neuroblastoma: High-Dose Melphalan and Autologous Unpurged Marrow Transplantation after Aggressive Surgery and Short Chemotherapy with Cisplatinum and Etoposide. Pediatric Hematology and Oncology 5:2, pages 125-135.
Read now
Read now
Articles from other publishers (11)
Jose Luis Lopez, Concepcion Pérez, Catalina Marquez, Patricia Cabrera, Jose Maria Perez, Gema Lucia Ramirez, Rafael Ordoñez, Juan Manuel Praena-Fernandez & Maria Jose Ortiz. (2011) Myeloablative therapy against high risk Ewing's sarcoma: A single institution experience and literature review. Reports of Practical Oncology & Radiotherapy 16:5, pages 163-169.
Crossref
Crossref
Frank Peinemann, Nicolaus Kröger, Carmen Bartel, Ulrich Grouven, Max Pittler, Rudolf Erttmann & Michael Kulig. (2011) High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation for Metastatic Rhabdomyosarcoma—A Systematic Review. PLoS ONE 6:2, pages e17127.
Crossref
Crossref
Frank Peinemann, Lesley A Smith, Mandy Kromp, Carmen Bartel, Nicolaus Kröger & Michael Kulig. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Rob PietersModesto Carli, Giovanni Cecchetto, Guido Sotti, Rita Alaggio & Michael Stevens. 2004. Paediatric Oncology, Third edition. Paediatric Oncology, Third edition
339
370
.
Brian H. KushnerPaul A. Meyers. (2001) How Effective Is Dose-Intensive/Myeloablative Therapy Against Ewing’s Sarcoma/Primitive Neuroectodermal Tumor Metastatic to Bone or Bone Marrow? The Memorial Sloan-Kettering Experience and a Literature Review. Journal of Clinical Oncology 19:3, pages 870-880.
Crossref
Crossref
M. CarliR. ColombattiO. OberlinM. StevensL. MasieroE. FrascellaE. KoscielniakJ. TreunerC. R. Pinkerton. (1999) High-Dose Melphalan With Autologous Stem-Cell Rescue in Metastatic Rhabdomyosarcoma. Journal of Clinical Oncology 17:9, pages 2796-2796.
Crossref
Crossref
V. Barbounis, G. Koumakis, M. Vassilomanolakis, H. Hatzichristou, S. Tsousis & A. P. Efremidis. (1995) A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation. Supportive Care in Cancer 3:5, pages 301-306.
Crossref
Crossref
Morris Kletzel, David L. Becton & D. H. Berry. (2006) Single institution experience with high‐dose cyclophosphamide, continuous infusion vincristine, escalating doses of VP‐16‐213, and total body irradiation with unpurged bone marrow rescue in children with neuroblastoma. Medical and Pediatric Oncology 20:1, pages 64-67.
Crossref
Crossref
C. R. Pinkerton, J. J. Groot-Loonen, P. H. Morris-Jones & J. Pritchard. (1991) Response rates in relapsed wilms' tumor. A need for new effective agents. Cancer 67:3, pages 567-571.
Crossref
Crossref
C. V. Viner, P. J. Selby, G. B. Zulian, M. E. Gore, M. E. Butcher, C. M. Wootton & T. J. McElwain. (1990) Ondansetron ? a new safe and effective antiemetic in patients receiving high-dose melphalan. Cancer Chemotherapy and Pharmacology 25:6, pages 449-453.
Crossref
Crossref
Peter J. Selby, Timothy J. McElwain, Ann C. Nandi, Timothy J. Perren, Raymond L. Powles, Colin R. Tillyer, Richard J. Osborne, Maurice L. Slevin & James S. Malpas. (1987) Multiple myeloma treated with high dose intravenous melphalan. British Journal of Haematology 66:1, pages 55-62.
Crossref
Crossref